×
2019 SABCS Overview
https://www.sabcs.org/2019-SABCS-sup-sup-/2019-SABCS-Overview

Oct 28th, 2019 - This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.

San Antonio Breast Cancer Symposium®: 2019 SABCS®
https://www.sabcs.org/2019-SABCS

Oct 28th, 2019 - An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer The San Antonio Breast Cancer Symposium is presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The driving force behind this collaboration is the shared m...

SABCS 2019 FAQs
https://www.sabcs.org/2019-SABCS-sup-sup-/2019-FAQs

Oct 28th, 2019 - This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant disease, to an international audience of academic and private physicians and researchers. The Symposium provides a forum for interaction, communication, and education for a broad spectrum of researchers, health professiona...

SABCS Schedule at a Glance
https://www.sabcs.org/Program/Schedule-at-a-Glance

Oct 28th, 2019 - The San Antonio Breast Cancer Symposium An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer. The San Antonio Breast Cancer Symposium® is presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine.

SABCS 2019 Symposium Overview
https://www.sabcs.org/Symposium-Overview-2019

Oct 28th, 2019 - Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a one-day regional conference, the Symposium has grown to a five-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

Susan G. Komen Names Three Recipients of the 2019 Brinker Awards for Scientific Distinction
https://ascopost.com/issues/october-25-2019/komen-names-recipients-of-brinker-awards-for-scientific-distinction/

Oct 25th, 2019 - Jane Visvader, PhD Geoffrey Lindeman, MBBS, PhD Matthew J. Ellis, BSc, MB, BChir, PhD, FRCP Susan G. Komen recently named Jane Visvader, PhD; George Lindeman, MBBS, PhD; and Matthew J. Ellis, BSc, MB, BChir, PhD, FRCP, as this year’s recipients of the Brinker Awards for Scientific Distinction. The 2019 Brinker Award winners will deliver keynote lectures at the upcoming 2019 San Antonio Breast C...

Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibit...
https://doi.org/10.1007/s10549-019-05464-w
Breast Cancer Research and Treatment; Qian X, Li Z et. al.

Oct 14th, 2019 - Endocrine therapy with aromatase inhibitors (AIs) is the cornerstone of adjuvant systemic treatment for postmenopausal patients with hormone receptor-positive breast cancer. It has become clear that hormone receptor-positive breast cancer carries a consistent risk of relapse up to 15 years after diagnosis. Extended duration of adjuvant AIs therapy after completing initial standard adjuvant AIs-...

Brinker Award winners to speak at #SABCS19
https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/ArticleID/176/Brinker-Award-winners-to-speak-at-SABCS19

Oct 14th, 2019 - Susan G. Komen® recently announced the recipients of the 2019 Brinker Awards for Scientific Distinction. They will receive their awards and present lectures at the 2019 San Antonio Breast Cancer Symposium® (SABCS®) at the Henry B. Gonzalez Convention Center, Dec. 10-14.

Puré and Weichselbaum to present plenary lectures
https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/ArticleID/175/Pur%C3%A9-and-Weichselbaum-to-present-plenary-lectures

Oct 7th, 2019 - Ellen Puré, PhD and Ralph Weichselbaum, MD, will present the plenary lectures at the 2019 San Antonio Breast Cancer Symposium® (SABCS®), Dec. 10-14.

SABCS selects abstracts, releases schedule
https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/ArticleID/174/SABCS-selects-abstracts-releases-schedule

Sep 19th, 2019 - Abstracts have been selected and presenters notified of their acceptance for the 2019 San Antonio Breast Cancer Symposium® Dec. 10-14 at the Henry B. Gonzalez Convention Center. More than 1,700 oral, spotlight and poster presentations will await attendees to the 42nd annual symposium which is the premier scientific conference focused solely on premalignant breast disease and breast cancer.

Joseph A. Sparano, MD, to Receive William L. McGuire Memorial Lecture Award
https://ascopost.com/issues/august-10-2019/joseph-a-sparano-md-to-receive-william-l-mcguire-memorial-lecture-award/

Aug 10th, 2019 - Joseph A. Sparano, MD, will receive the William L. McGuire Memorial Lecture Award at the 2019 San Antonio Breast Cancer Symposium (SABCS), to be held December 10–14. The McGuire Award was established in 1992 to honor William L. McGuire, MD, who, along with Charles A. Coltman, MD, founded the SABCS in 1977. Joseph A. Sparano, MD Dr. Sparano is being recognized for a career distinguished by leade...

Forums offer insights for early-career investigators
https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/ArticleID/171/Forums-offer-insights-for-early-career-investigators

Jul 29th, 2019 - The San Antonio Breast Cancer Symposium® is not only the leading scientific conference on the diagnosis and treatment of premalignant breast disease and breast cancer, there are outstanding opportunities for young scientists, clinicians and investigators to gain vital career insights.

SABCS awards Joseph A. Sparano the William L. McGuire Memorial Lecture Award
https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/pageindex10112/2

Jul 8th, 2019 - Joseph A. Sparano, MD will receive the William L. McGuire Memorial Lecture Award at the 2019 San Antonio Breast Cancer Symposium.

Evidence Lacking That Denosumab Alters the Course of Breast Cancer
https://ascopost.com/issues/june-25-2019/evidence-lacking-that-denosumab-alters-the-course-of-breast-cancer/

Jun 25th, 2019 - I am writing to provide personal context to my column on adjuvant denosumab or bisphosphonates for resected breast cancer, which appears on page 52 in this issue of The ASCO Post. I have been upset since 2013 that adjuvant zoledronate has been recommended for women with breast cancer onset after age 55 without a positive trial restricted to this population showing benefits in the incidence of b...

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negativ...
https://meetinglibrary.asco.org/record/171873
Adam Brufsky, MD, PhD

Jun 2nd, 2019 - Background: COLET showed that the addition of C (MEK1/2 inhibitor) to P resulted in an increased ORR (38%; Brufsky, SABCS 2017); IMpassion130 demonstrated clinical benefit with the combination of PD-L1 inhibitor A and nP as 1L tx for pts with mTNBC (Schmid, N Engl J Med, 2018). We investigated the efficacy and safety of A + C + P/nP in pts with mTNBC, as this combination may target multiple can...

Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer.
https://meetinglibrary.asco.org/record/176032
Prashanth Reddy Moku, BS

Jun 2nd, 2019 - Background: In MA.31 the trastuzumab-taxane combination led to longer PFS than lapatinib-taxane in HER2+ metastatic breast cancer (MBC). In MA.31 we previously reported the prognostic/predictive utility of pretreatment serum PD-L1 (SABCS 2018, PD3-10) and serum activin A (SABCS 2016, P6-07-06) separately; here we evaluate them combined. Methods: MA.31 accrued 652 centrally and/or locally-identi...

A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator’s choice in HER2-low breast cancer.
https://meetinglibrary.asco.org/record/176744
Shanu Modi, MD

Jun 2nd, 2019 - Background: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have greatly improved survival in HER2+ breast cancer (BC). However, there are many more BC patients with HER2-low expression (immunohistochemistry [IHC] 1+ or 2+/ in situ hybridization-negative), for whom no HER2-targeted therapies are approved. [Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a) is an antibody...

FDA approves T-DM1 as adjuvant treatment
https://www.mdedge.com/hematology-oncology/article/200238/breast-cancer/fda-approves-t-dm1-adjuvant-treatment?channel=39313
Laura Nikolaides

May 6th, 2019 - The Food and Drug Administration has approved the antibody-drug conjugate trastuzumab emtansine (T-DM1) for adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant treatment with a taxane and trastuzumab (Herceptin). Approval of adjuvant T-DM1, marketed as Kadcyla, was based on a reduced risk of breast cancer recurrence or death.

IMpassion130 Substudy: Atezolizumab/Nab-Paclitaxel Survival Benefits Limited to PD-L1–Positive Triple-Negative Breast Cancer
https://ascopost.com/issues/march-25-2019/impassion130-substudy/

Mar 25th, 2019 - THE PHASE III IMpassion130 trial, first reported at the European Society for Medical Oncology (ESMO) 2018 Congress1 and published in The New England Journal of Medicine,2 found that the combination of front-line atezolizumab plus nab-paclitaxel significantly improved disease-free and overall survival in women with metastatic triple-negative breast cancer vs placebo plus nab-paclitaxel in an int...

Neoadjuvant Palbociclib Plus Letrozole Reduces Ki67 Levels
https://ascopost.com/issues/march-10-2019/neoadjuvant-palbociclib-plus-letrozole-reduces-ki67-levels/

Mar 10th, 2019 - Mitch Dowsett, PhD In the neoadjuvant setting, adding palbociclib to letrozole significantly enhanced the suppression of malignant cell proliferation, as measured by Ki67 levels, in patients with primary estrogen receptor–positive breast cancer but did not increase the clinical response rate over 14 weeks, according to results from the multinational randomized phase II PALLET trial presented at...